2023, Scientific Sessions, Session Coverage
  • Speakers analyze strategies to improve type 2 diabetes outcomes for adolescents

    Speakers analyze strategies to improve type 2 diabetes outcomes for adolescents

    Following the COVID-19 pandemic, researchers observed an increase in type 2 diabetes among adolescents. Experts, including Katie O’Sullivan, MD, presented three strategies to help address the disease in youths: mobilize an interdisciplinary team, explore medical or surgical treatments, and provide community intervention programs.


  • ICYMI Presenter Profile: Joint ADA/ISPAD Symposium—Why Aren’t All Guidelines the Same? A Focused Review of Recommendations from ISPAD 2022 and ADA 2023

    ICYMI Presenter Profile: Joint ADA/ISPAD Symposium—Why Aren’t All Guidelines the Same? A Focused Review of Recommendations from ISPAD 2022 and ADA 2023

    Priya Prahalad, MD, PhD, previews a presentation at the 83rd Scientific Sessions. Registered participants can view select recordings, including of this session, on the meeting’s virtual platform through August 28.


  • ADA and partners develop consensus statement on person-reported outcomes

    ADA and partners develop consensus statement on person-reported outcomes

    A forthcoming consensus statement on PROs looks beyond numbers associated with diabetes—glucose levels, A1C, time in range—to the myriad ways the disease affects daily life. Because diabetes relies on the patient’s own engagement in therapeutic behaviors, integrating PROs into clinical models for care is crucial, explained the authors, including Jennifer L. Sherr, MD, PhD.


  • Physicians debate the comparative benefits of smart insulin delivery and pancreatic cell transplant

    Physicians debate the comparative benefits of smart insulin delivery and pancreatic cell transplant

    The debate continues over using beta-cell replacement or automated insulin delivery in the treatment of patients with type 1 diabetes. Michael R. Rickels, MD, MS, presented support for the biological solution provided by islet transplantation, while Bruce A. Buckingham, MD, presented data supporting the artificial pancreas.


  • Experts discuss the physiology of exercise and clinical management of athletes with type 1 diabetes

    Experts discuss the physiology of exercise and clinical management of athletes with type 1 diabetes

    Michael Riddell, PhD, and Lori M. Laffel, MD, MPH, provided insight into the unique needs of athletes—children and adults—who live with type 1 diabetes. Different forms of exercise affect glycemia differently, making it important for the type, duration, and intensity of exercise to be factored into the athlete’s care plan.


  • ICYMI Presenter Profile: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

    ICYMI Presenter Profile: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

    Filip K. Knop, MD, PhD, previews a presentation at the 83rd Scientific Sessions. Registered participants can view select recordings, including of this session, on the meeting’s virtual platform through August 28.


  • Time in range becomes an increasingly important diabetes target

    Time in range becomes an increasingly important diabetes target

    A1C has long been the gold standard for assessing glycemic control in diabetes over time, but continuous glucose monitoring (CGM) metrics such as time in range (TIR) are increasingly becoming popular because they represent real-time results. Revital Nimri, MD, and other experts discussed the role of TIR and other CGM metrics that use the most…


  • Panelists look at impact of SGLT2 inhibitors, GLP-1 receptor agonists in CVD and diabetes

    Panelists look at impact of SGLT2 inhibitors, GLP-1 receptor agonists in CVD and diabetes

    Growing evidence indicates SGLT2 inhibitors and GLP-1 receptor agonists have beneficial effects not only in patients with type 2 diabetes but also those at risk for cardiovascular disease. Physicians and scientists, including Darren K. McGuire, MD, MHSc, presented findings from trials that demonstrate positive clinical outcomes.


  • Symposium examines type 1 diabetes in other settings such as cancer immunotherapy and celiac disease

    Symposium examines type 1 diabetes in other settings such as cancer immunotherapy and celiac disease

    Cancer immunotherapy, monogenic primary immune deficiencies, and celiac disease may have pathologic links to type 1 diabetes. Four experts, including Arabella Young, PhD, discussed ways these conditions may be linked, and in some cases how they can be screened for together.


  • Session offers in-clinic tips for obtaining, interpreting diabetes device data

    Session offers in-clinic tips for obtaining, interpreting diabetes device data

    More than 3 million Americans use continuous glucose monitoring, which provides a plethora of useful data for clinicians. Obtaining and interpreting that data continues to present challenges. Rebecca Rick Longo, MSN, ACNP-BC, CDCES, offered solutions for efficiently downloading the data, and Cari Berget, MPH, RN, CDCES, explained a three-step process for reviewing and using the…